A pilot study found that the insulin-treated type 2 diabetes patients' levels of A1C, which reflects average blood sugar for the last two to three months, was reduced comparably like those of intensive oral therapy. They tolerated the treatment without severe hypoglycemia and weight gain.
A pilot study found that the insulin-treated type 2 diabetes patients' levels of A1C, which reflects average blood sugar for the last two to three months, was reduced comparably like those of intensive oral therapy. They tolerated the treatment without severe hypoglycemia and weight gain.
Share this Article
Recommended